... specific functional expression programs correlated with fluctuations in various #Tcell subsets, which may be associated with #AML progression and relapse. Furthermore, our analysis of cellular communication networks led to the identification of #VISTA, #CD244, and #TIM3 as potential #immunotherapeutic targets in pediatric AML."

https://pubmed.ncbi.nlm.nih.gov/38844062/

Nice work by Yuan et al., using #scRNAseq and #scTCRseq. No huge discoveries, but of interest nonetheless.

#science #cancer #immunology

Single-cell transcriptomic analysis of the immune microenvironment in pediatric acute leukemia - PubMed

Relapse and treatment resistance pose significant challenges in the management of pediatric B cell acute lymphoblastic leukemia (B-ALL) and acute myeloid leukemia (AML). The efficacy of immunotherapy in leukemia remains limited due to factors such as the immunosuppressive tumor microenvironment (TME …

PubMed

A recently developed ⭐️#cancer #vaccine for dogs⭐️ is showing promising results in clinical trials, which have been running since 2016, and there's hope that some of the benefits of the vaccine could be translated into human cancer treatments.

More than 300 dogs have been treated with the vaccine to date, and the twelve--month survival rate for canines with certain cancers has been lifted from about 35 percent to 60 percent. Tumors in many of the animals have also shrunk.

Known officially as the #Canine #EGFR/#HER2 #Peptide #Cancer #Immunotherapeutic, the treatment grew out of studies of autoimmune diseases, where the immune system damages the body's own tissue rather than any invading threats.
The vaccine is designed to get the immune system to attack cancer instead.

In many ways tumors are like the targets of autoimmune diseases," says rheumatologist #Mark #Mamula, from the Yale University School of Medicine.

"Cancer cells are your own tissue and are attacked by the immune system. The difference is we want the immune system to attack a tumor."

As outlined in a 2021 study by Mamula and colleagues, the treatment gets the immune cells to produce antibody defenses, which attach themselves to tumors and interfere with their growth patterns.

Specifically, these antibodies hunt down two proteins: 🔸epidermal growth factor receptor 🔸( #EGFR ) and 🔸human epidermal growth factor receptor 2🔸 ( #HER2 ).

Mutations causing overexpression of these proteins drive uncontrolled cell division in some human and canine cancers.

https://www.sciencealert.com/breakthrough-cancer-vaccine-for-dogs-is-truly-revolutionary-scientist-says

Breakthrough Cancer Vaccine For Dogs Is 'Truly Revolutionary', Scientist Says

A recently developed cancer vaccine for dogs is showing promising results in clinical trials, which have been running since 2016, and there's hope that some of the benefits of the vaccine could be translated into human cancer treatments.

ScienceAlert
Join us Thurs, May 4, at noon CT/1 pm ET as Dr. Sarah K. Tasian of Children’s Hospital of #Philadelphia presents “Emerging Therapies for Pediatric Leukemia.” Tasian will review the biology of childhood B-acute lymphoblastic #leukemia and discuss emerging precision medicine therapies and #immunotherapeutic approaches for specific leukemia subtypes. Register. https://bit.ly/SOCC23-MAS #SOCC23 #AcuteLymphoblasticLeukemia #PrecisionMedicine #Immunotherapy
Science of Childhood Cancer Lecture Series

A 15-week virtual lecture series focused on key questions in pediatric cancer research. View the expert speakers and recordings of prior seminars.

https://www.immunotherapy-clinic-ikiru.com/gcmaf/

Any functional medicine patients who might respond to the effects?

Gcmaf in North America?

#functionalmedicine
#cancer #gcmaf #immunotherapeutic

GcMAF - Immunotherapy cancer and chronic disease

GcMAF Background GcMAF (Gc Protein-derived Macrophage Activating Factor) occurs naturally in the human body and activates macrophages to destroy cancer cells and foreign invaders such as bacteria and viruses. Serious illnesses like cancer, HIV and viral hepatitis are destroyed by GcMAF.   

Immunotherapy cancer and chronic disease

#introduction !

I’m an immunologist from #Denmark, with a PhD from #NIH and #UniversityofCambridge where I used #CRISPR screens to dissect #Tcell integrin activation.

Now I’m a postdoc at #TechnicalUniversityofDenmark (#DTU ). My interest currently revolves around using/developing novel CRISPR tools for T cell editing as well as using CRISPR to identify novel #immunotherapeutic targets.

Also I love my 2 year old son and my wife, and have a passion for sailing and biotech innovation!